Menopur

Menotropin, the active ingredient in Menopur, is a gonadotropin presented as a powder for solution for injection for intramuscular and subcutaneous use. It provides combined follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity to stimulate ovarian follicular development and ovulation in women and to support spermatogenesis in men.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU marketing authorisation requirements and is distributed under strict quality‑assured conditions.

Menopur is a gonadotropin used in fertility treatment protocols to stimulate follicular development and ovulation. - Induction of ovulation in anovulatory women: promotes follicular growth to achieve timed ovulation for intra‑uterine insemination or timed intercourse. - Controlled ovarian stimulation for assisted reproductive technologies (e.g., IVF): supports multiple follicle development to increase oocyte yield. - Support of follicular development in women undergoing intrauterine insemination: enhances the number and quality of mature follicles for IUI cycles.

Menopur may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Injection site pain or erythema: mild discomfort or redness at the injection site. - Abdominal bloating or discomfort: transient abdominal fullness. - Headache: mild to moderate intensity. - Nausea: occasional mild nausea. - Ovarian hyperstimulation syndrome (mild): mild abdominal distension with mild weight gain.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): rapid weight gain, ascites, respiratory distress. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Allergic reactions: rash, urticaria, or anaphylaxis. - Multiple pregnancy: twins or higher-order gestations. - Ectopic pregnancy: implantation outside the uterus.

Before initiating Menopur therapy, clinicians should consider several precautionary measures to minimise risk. - Assess baseline ovarian reserve: perform ultrasound and hormone testing to tailor dose. - Screen for contraindications: avoid use in active ovarian cysts, uncontrolled thyroid disease, or estrogen‑dependent tumors. - Monitor estradiol levels: frequent serum estradiol checks reduce risk of severe ovarian hyperstimulation. - Perform ultrasound surveillance: track follicle size and number during stimulation cycles. - Educate patients on symptoms of OHSS: advise immediate medical attention for rapid weight gain, abdominal pain, or shortness of breath. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other medications or clinical conditions that affect hormone balance or coagulation.

Major Interactions (Avoid): - Gonadotropin‑releasing hormone (GnRH) antagonists: may blunt the intended ovarian response. - Aromatase inhibitors: can reduce estrogen synthesis, counteracting Menopur’s effect. - Anticoagulants (e.g., warfarin): increased risk of thromboembolic complications in ovarian hyperstimulation.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: altered metabolism may affect response; monitor thyroid function. - Corticosteroids: may influence fluid balance and OHSS risk; observe closely. - Diuretics: can mask early signs of fluid retention associated with OHSS.